Navigation Links
Point Therapeutics Announces Preclinical Data Presentations at,Upcoming American Association of Cancer Research Annual Meeting

BOSTON--(BUSINESS WIRE)--Apr 13, 2007 - Point Therapeutics, Inc. (NASDAQ: POTP) today reported the upcoming presentation of preclinical data at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) taking place in Los Angeles, California, April 14-18, 2007. The AACR poster presentations report on preclinical studies on talabostat's novel mechanism of action.

Additional details for the AACR presentations are as follows:

Presentation Date and Time: Monday, April 16, 2007, 8:00 AM -12:00 PM PT

Abstract #1894: Immune mechanisms of action of talabostat: a dipeptidyl peptidase targeted anti-tumor agent

Presentation Date and Time: Wednesday, April 18, 2007, 8:00 AM -12:00 PM PT

Abstract #5622: The anti-tumor potential of inhibitors of the DASH proteases in a mouse model of human breast cancer

The posters associated with the abstracts will be available on the Point Therapeutics' web site at www.pther.com immediately following their presentation.

About Point Therapeutics, Inc.:

Point is a Boston-based biopharmaceutical company currently studying its lead product candidate, talabostat, in two Phase 3 double blind, placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.

Contact

Point Therapeutics, Inc.
Sarah Cavanaugh, 617-933-7508
Director, Corporate Communications


'"/>




Page: 1

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Analyzers Offer Point-of-Care Lipid Panels
3. Hemoglobin Testing at the Point of Care
4. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
5. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
6. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
10. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
Breaking Medicine News(10 mins):